Q-omics provides the consensus-scored YPEL3 profile across patient tissues and cancer cell-line models. YPEL3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, YPEL3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, YPEL3 RNA expression shows 14,654 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRC, and THYM as cancer lineages where YPEL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for YPEL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes YPEL3 survival associations across molecular data types. YPEL3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible YPEL3 RNA expression–survival associations across cancer types. High YPEL3 expression shows favorable associations in MESO, UVM, HNSC, CESC, ACC and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for YPEL3 RNA expression.
This table summarizes YPEL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for YPEL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. YPEL3 shows lower tumor expression in KICH, LUSC and UCEC and higher tumor expression in KIRC, LIHC and THCA. The KIRC box plot shows higher YPEL3 RNA expression in tumor versus normal tissue (log2 FC = +0.697, t-test p < 0.001).
This table shows molecular features associated with YPEL3 in patient tissues and cancer cell lines. In patient samples, YPEL3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, YPEL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
